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Abstract

Imaging

• Human prion disease is a rare, highly progressive neurodegenerative
disease that is ultimately fatal.
• The majority of cases occur sporadically, although some may be
genetic or acquired.
• Here, we highlight a case of a 64-year-old woman who presents with
rapidly declining memory loss, behavior changes, headaches, and
gait disturbance approximately one week following administration of
the second dose of the novel Pfizer-BioNTech messenger ribonucleic
acid (mRNA) COVID-19 vaccine.

• After extensive investigation, conclusive evidence identified the fatal
diagnosis of sporadic Creutzfeldt-Jakob disease.

Introduction
Human prion diseases were first described in the early 1920s and
are delineated into three categories: sporadic, inherited, or acquired
by way of infection. Of the sporadic type, there are Creutzfeldt-Jakob
disease (CJD), fatal insomnia, and variably protease-sensitive
prionopathy. Approximately 90% of cases of prion disease are
sporadic CJD, which can be further divided into five subtypes based
on clinical features, histological findings on autopsy, and molecular
structure of the abnormal protein [1]. The incidence of sCJD is very
rare, approximately 1-2 cases per one million per population. In the
case presented herein, the plausibility of the Pfizer-BioNTech
COVID-19 vaccine triggering sCJD is explored.

Case
❖ A 64-year-old woman with a past medical history of bipolar
depression and anxiety presents with rapidly progressive
dementia, behavioral changes, headaches, and gait disturbance
approximately one week after receiving the second dose of the
Pfizer-BioNTech COVID-19 vaccine.
❖ Physical exam was essentially unremarkable except for confusion
and significant distress regarding her condition.
❖ Initial labs, toxicology screening, and imaging were unremarkable
except for a mildly increased white blood cell count.
❖ Psychiatry and neurology were consulted.
❖ Magnetic resonance (MR) imaging of the brain showed cortical
diffusion restriction involving the bilateral frontal lobes, bilateral
parietal lobes, and paramedian bilateral occipital lobes.
❖ Lumbar puncture: positive via the newest, highly sensitive real-time
quaking-induced conversion (RT-QuIC) testing.
❖ T-tau protein measured at 38,979 (reference < 0-1,149).
❖ 14-3-3 protein was positive, neuron-specific enolase resulted at
16.3 (reference < 8.9).
❖ Exhibiting progressively worsening pyramidal and extrapyramidal
symptoms, as well as akinetic mutism.
❖ Based on the Center for Disease Control and Prevention’s
diagnostic criteria, the findings place her case as
probable sporadic CJD with a definitive diagnosis to be made by a
proper autopsy with neuropathological studies.
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Discussion
• Normal prion protein is converted into an infectious, autoenzymatic protein that aggregates in the brain tissue destroying
neuronal cells leading to extensive neurodegeneration.
• Human prion protein (PrP), is encoded by the PrP gene, PRNP,
which is located on the short arm of chromosome 20.
• Conversion to the diseased prion protein, termed PrPSc, is
determined by PRNP polymorphism involving methionine (Met)
or valine (Val) at codon 129 and prion strain (type 1 PrPSc or
type 2 PrPSc).
• Etiology has been thought to be a mostly sporadic disease with
no known specific cause.
• Retrospective case-control study in the United Kingdom found
that all sporadic Creutzfeldt-Jakob disease (sCJD) cases from
1990 - 1998 lived close together, suggesting plausible
precipitating factor.
• mRNA contained in the Pfizer-BioNTech COVID-19 vaccine has
the potential to bind to specific proteins and cause pathologic
misfolding.
• Various portions of the COVID-19 mRNA Pfizer-BioNTech
vaccine to have a high affinity for cytoplasmic proteins such as
TAR DNA binding proteins (TDP-43) and Fused in Sarcoma
(FUS) .
• Spike protein, which is translated by the mRNA, can increase
intracellular zinc, which has been shown to cause the
conversion of TDP-43 into its pathological prion.
• Kuo et.al demonstrated how TDP-43 binds to mRNA transcripts
with long UG-repeats.
• Pfizer-BioNTech’s COVID-19 vaccine contains many of these
specific sequences.
• Tetz and Tetz identified a prion-like domain found in the
receptor-binding domain of the S1 region of the SARS-CoV-2
spike protein.
• A case reported a previously healthy 60-year-old man who
developed sudden onset sCJD with concurrent onset of
symptoms of COVID-19.
• Case of a patient with sCJD whom also had positive serum
neuronal antibodies to the voltage-gated potassium channel
complex (VGKC complex) and glycine receptor (GlyR)
antibodies, suggesting a possible auto-immune mechanism.
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